Business ❯ Pharmaceutical Industry ❯ Stock Market
Bavarian Nordic Soleno Therapeutics Biohaven Pharmaceuticals Kenvue, Inc. Skye Bioscience Inc. Bristol Myers Squibb
Two remaining Phase 3 studies in atrial fibrillation and secondary stroke prevention continue, with topline results expected in 2026.
